Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The antibiotic rifaximin is used to treat non-constipated irritable bowel syndrome (IBS). Methane production is associated with constipation and its severity in constipation-predominant IBS (C-IBS). A previous retrospective study suggested that rifaximin and neomycin was superior to neomycin alone in improving symptoms in methane-positive subjects.
To determine the effectiveness of neomycin alone or with rifaximin in improving symptoms in methane-positive C-IBS subjects.
A double-blind, randomized, placebo-controlled trial was performed from 2010 to 2013 at three tertiary care centers. Subjects aged 18–65 with C-IBS (Rome II criteria) and breath methane (>3 ppm) meeting the inclusion and exclusion criteria were recruited. Subjects completed a baseline symptom questionnaire rating the severity of abdominal and bowel symptoms on a visual analog scale and were randomized to receive neomycin and placebo or neomycin and rifaximin for 14 days. Symptom severity was assessed by weekly questionnaire for 2 weeks of therapy and 4 additional weeks of follow-up.
Thirty-one subjects (16 neomycin and placebo, 15 neomycin and rifaximin) were included in the intention-to-treat analysis. Constipation severity was significantly lower in the neomycin and rifaximin group (28.6 ± 30.8) compared to neomycin alone (61.2 ± 24.1) (P = 0.0042), with greater improvement in constipation (P = 0.007), straining (P = 0.017) and bloating (P = 0.020), but not abdominal pain. In the neomycin and rifaximin group, subjects with methane <3 ppm after treatment reported significantly lower constipation severity (30.5 ± 21.8) than subjects with persistent methane (67.2 ± 32.1) (P = 0.020).
Rifaximin plus neomycin is superior to neomycin alone in improving multiple C-IBS symptoms. This effect is predicted by a reduction in breath methane.
- Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the Unites States. Gastroenterology. 2002;122:1500–1511. CrossRef
- Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut. 1999;45:II43–II47.
- Halvorson HA, Schlett CD, Riddle MS. Post-infectious irritable bowel syndrome: a meta-analysis. Am J Gastroenterol. 2006;101:1894–1899. CrossRef
- Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Aliment Pharmacol Ther. 2007;26:535–544. CrossRef
- Shah ED, Basseri RJ, Chong K, et al. Abnormal breath testing in IBS: a meta-analysis. Dig Dis Sci. 2010;55:2441–2449. CrossRef
- Posserud I, Stotzer PO, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56:802–808. CrossRef
- Pyleris E, Giamarellos-Bourboulis EJ, Tzivras D, et al. The prevalence of overgrowth by aerobic bacteria in the small intestine by small bowel culture: relationship with irritable bowel syndrome. Dig Dis Sci. 2012;57:1321–1329. CrossRef
- Chang C, Funari V, Giamarellos-Bourboulis EJ, et al. Deep sequencing reveals that the microbiome of the human duodenum is unique and unrelated to stool bacterial profiling. Gastroenterology. 2013;144:S908.
- Pimentel M, Lembo A, Chey WD, et al. Rifaximin therapy for the treatment of irritable bowel syndrome without constipation. N Engl J Med. 2011;364:22–32. CrossRef
- Kunkel D, Basseri RJ, Makhani MD, et al. Methane on breath test is associated with constipation: a systematic review and meta-analysis. Dig Dis Sci. 2011;56:1612–1618. CrossRef
- Attaluri A, Jackson M, Valestin J, et al. Methanogenic flora is associated with altered colonic transit but not stool characteristics in constipation without IBS. Am J Gastroenterol. 2010;105:1407–1411. CrossRef
- Pimentel M, Lin HC, Enayati P, et al. Methane, a gas produced by enteric bacteria, slows intestinal transit, an augments small intestinal contractile activity. Am J Physiol. 2006;290:G1089–G1095.
- Chatterjee S, Park S, Low K, et al. The degree of methane production in IBS correlates with the severity of constipation. Am J Gastroenterol. 2007;102:837–841. CrossRef
- Pimentel M, Chatterjee S, Chow EJ, et al. Neomycin improves constipation predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: sub-analysis of a double blind randomized controlled study. Dig Dis Sci. 2006;51:1297–1301. CrossRef
- Low K, Hwang L, Hua J, et al. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. J Clin Gastroenterol. 2010;44:547–550.
- Kim G, Deepinder F, Morales W, et al. Methanobrevibacter smithii is the predominant methanogen in patients with constipation predominant IBS and methane on breath. Dig Dis Sci. 2012;57:3213–3218. CrossRef
- Menees SB, Maneerattannaporn M, Kim HM, et al. The effect and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol. 2012;107:28–35. CrossRef
- Antibiotic Treatment of Constipation-Predominant Irritable Bowel Syndrome
Digestive Diseases and Sciences
Volume 59, Issue 6 , pp 1278-1285
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Irritable bowel syndrome
- Breath methane
- Industry Sectors
- Author Affiliations
- 1. GI Motility Program, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA
- 2. Department of Biostatistics, Cedars-Sinai Medical Center, Los Angeles, CA, USA
- 3. Division of Gastroenterology, Mayo Clinic, Scottsdale, AZ, USA
- 4. Section of Gastroenterology/Hepatology, Georgia Regents University, Augusta, GA, USA